Navigation Links
Cardinal Health, FDA Amend Infusion Pump Consent Decree
Date:2/17/2009

DUBLIN, Ohio, Feb. 17 /PRNewswire-FirstCall/ -- Cardinal Health today announced it has reached agreement with the Food and Drug Administration (FDA) on an amended consent decree regarding the company's infusion pump products.

Cardinal Health has operated under a consent decree since February 2007 for its Alaris(R) SE pumps, which resulted in the company implementing a new quality system on April 2, 2008. Under the amended agreement, which is subject to approval by the U.S. District Court for the Southern District of California, Cardinal Health will conduct a thorough review of its broader line of infusion pump products within 60 days and submit a corrective action plan to the FDA that outlines all planned modifications to any infusion pump products. Within 100 days, the company will have an independent expert inspect and certify whether the company's infusion pump operations are in conformity with the Quality System Regulation and certain other provisions of the Federal Food, Drug, and Cosmetic Act. Also within 100 days, the company will have an independent expert inspect and certify whether its recall procedures and all ongoing infusion pump recalls are in compliance with the Act and determine whether additional remedial action should be taken.

The FDA alleges in the amended consent decree that based on a January 2008 inspection, certain Cardinal Health infusion pumps do not satisfy the standards of the Act. The amended agreement does not impact the company's ability to market and sell its broader line of infusion pump products, except for the Alaris SE pump.

"We are taking the FDA's observations -- and our obligation to deliver safe and effective products -- very seriously," said David Schlotterbeck, Cardinal Health vice chairman and chief executive officer of Clinical and Medical Products. "We will continue to improve our systems as we prepare to meet the additional requirements of the amended consent decree."

Customers using Alaris(R) brand infusion products who have questions about this announcement should contact 1-800-625-6627 or SupportCenter@cardinalhealth.com.

About Cardinal Health

Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is a $91 billion, global company serving the health care industry with products and services that help hospitals, physician offices and pharmacies reduce costs, improve safety, productivity and profitability, and deliver better care to patients. With a focus on making supply chains more efficient, reducing hospital-acquired infections and breaking the cycle of harmful medication errors, Cardinal Health develops market-leading technologies, including Alaris(R) IV pumps, Pyxis(R) automated dispensing systems, MedMined(TM) electronic infection surveillance service, VIASYS(R) respiratory care products and the CareFusion(TM) patient identification system. The company also manufactures medical and surgical products and is one of the largest distributors of pharmaceuticals and medical supplies worldwide. Ranked No. 19 on the Fortune 500, Cardinal Health employs more than 40,000 people on five continents. More information about the company may be found at http://www.cardinalhealth.com.


'/>"/>
SOURCE Cardinal Health, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cardinal Health Announces New Name for Spinoff Company
2. Cardinal Rigali to Congress: Keep Existing Pro-Life Laws
3. Cardinal Health Reports Second Quarter Results
4. Cardinal Health Updates FY09 Outlook
5. Cardinal Health, SRI Surgical Sign Five-Year Agreement For Surgical Kits
6. Cardinal Health Announces Preliminary Shareholder Voting Results at Annual Meeting
7. Cardinal Health Reports First Quarter Results
8. Positive Picture of Independent Community Pharmacies Emerges With Release of 2008 NCPA Digest, Sponsored by Cardinal Health
9. Cardinal Health Reports Fiscal 2008 Results, Provides Fiscal 2009 Outlook
10. Cardinal Health Declares Regular Quarterly Dividend
11. Cardinal Health Expands Leader(R) Offering To Help Independent Pharmacies Strengthen Patient Relationships, Solidify Role As Local Health Care Experts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... 2016 , ... W.S. Badger Co. Inc ., the maker of certified ... as one of the best small businesses for new dads by Fatherly, the digital ... businesses providing progressive benefits to new parents on the organization’s 2016 Best Places ...
(Date:5/27/2016)... ... ... This campaign aims to provide a path to improved education and awareness ... change. , As nearly 795,000 Americans suffering from a new or recurrent stoke each ... an estimated 129,000 of these people dying from stroke, it’s become our nation’s fifth-leading ...
(Date:5/27/2016)... Texas (PRWEB) , ... May 27, 2016 , ... ... satisfying Army body fat composition regulations. This is the first time that Coolsculpting ... normally screened at least every six months to ensure they meet the prescribed body-fat ...
(Date:5/27/2016)... ... 2016 , ... Each year Standard Process Inc. ... this year’s Life University winner of a $2,500 scholarship from Standard ... Awards ceremony. , Outerbridge is approaching her last quarter at Life University in ...
(Date:5/26/2016)... ... 26, 2016 , ... There are many ways to cook a hot dog, ... that Americans prefer their dogs straight off the grill. Of the 90 percent of ... way to cook a hot dog, far outpacing other cooking methods such as steaming ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), ... and Orphan Diseases, today announced that President & CEO Gerald ... SeeThru Equity MicroCap Conference   Where: ... , NY When: Tuesday, May 31 st , ... Where: Grand Hyatt Hotel, 109 East 42 nd St, ...
(Date:5/26/2016)... 2016   Change Healthcare , a ... solutions and technology-enabled services designed to enable ... a strategic channel partnership with SourceMed, the ... and revenue cycle management services that empower ... clinics to optimize revenue, operational efficiency and ...
(Date:5/25/2016)... and GERMANTOWN, Maryland , May ... QGEN ; Frankfurt Prime Standard: QIA) today announced that ... with Therawis Diagnostics GmbH to develop and commercialize predictive assays ... market PITX2 as a marker to predict effectiveness of anthracycline ... "We are pleased to partner with Therawis, which ...
Breaking Medicine Technology: